According to a study presented at the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium, the cisplatin shortage raised costs for practices within the U.S. Oncology Network by 16% for treating head and neck cancers. The increase was largely driven by the utilization of alternative drugs like cetuximab, whose average administration cost ($2,607) dwarfs that of cisplatin ($18).